Business
Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress
Jaguar continues its sharp strategic focus on its global development program for crofelemer for rare-disease intestinal failure (IF) indications; all patients
About this update from Jaguar Health, Inc.
[{"type":"text","content":"Jaguar continues its sharp strategic focus on its global development program for crofelemer for rare-disease intestinal failure (IF) indications; all patients with microvillus inclusion disease (MVID) suffer from IF, as do a significant proportion of patients with short bowel syndrome (SBS). The global market for SBS, including IF, is estimated to reach approximately $8.0 billion by 2033.Near-term milestones for intestinal failure program buttressed by groundbreaking results of parenteral support reduction ranging from 12 to 37% in ongoing proof-of-concept study of crofelemer in pediatric IF patients; Abstract for long-term safety and efficacy of crofelemer liquid formulation submitted for presentation at ESPGHAN (European Society for Paediatric Gastroenterology Hepatology and Nutrition) Annual Meeting in 2026.Click here to view video update from Jaguar CEO Lisa Conte on company's near-term catalysts. SAN FRANCISCO, CA / ACCESS Newswire / April 2, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced that it is a silver-level sponsor of the April 2-4, 2026 Annual ELITE PED-GI Congress in Abu Dhabi in the United Arab Emirates (UAE).As previously announced, Napo is supporting an independent investigator-initiated proof-of-concept study of crofelemer liquid formulation in pediatric intestinal failure (IF) patients with in microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF) at Sheikh Khalifa Medical City in Abu Dhabi, UAE. The study's principal investigator, Dr. Mohamad Miqdady, previously presented an update on this study at the April 2025 ELITE PED-GI Congress, and patients participating in the study have continued to receive crofelemer treatment for more than one year.Intestinal failure is a debilitating condition that often requires patients to receive life-sustaining fluids, electrolytes and nutrients through intravenous administration, which consists of total parenteral nutrition (TPN) with supplemental intravenous fluids, which together constitute PS. Many intestinal failure patients require PS up to 7 days a week, and sometimes for 20 hours or more per day. While crucial for intestinal failure patients, PS is associated with significant toxicities to patients, similar to some toxicities associated with chemotherapy, often causing serious health problem...